Lupin launches generic Brivaracetam oral solution in US to treat epilepsy

Brivaracetam is the bioequivalent to Briviact Oral Solution, 10 mg/mL, of UCB

Akums demonstrates clinical versatility of Lacosamide in epilepsy care

Clinical evidence has consistently highlighted lacosamide’s efficacy and safety.

Zhimeng Biopharma’s investigational drug approved to begin phase 2 epilepsy clinical trial in China

This approval follows the CDE’s clearance in July of this year for Phase 2/3 clinical studies of CB03-154 in amyotrophic lateral sclerosis

Aster Whitefield Hospital and government partner for free epilepsy camp in Kolar

The initiative aimed to reach and support individuals suffering from epilepsy through early detection and effective disease management

KIMS Hospitals launches Institute of Advanced Neurosciences in Bengaluru

New Centre of Excellence at Electronic City campus to offer specialised care in epilepsy, cerebrovascular disorders, neurointervention, skull base and spine surgery

Beacon raises $132M+ to bring AI-driven sleep diagnostics to masses

The device aims to bring precision neuroscience into clinical trials, accelerating drug development

KIMS Hospitals launches cutting-edge Neurosciences Institute in Mahadevapura

Alembic Pharma secures USFDA approval for generic Lamotrigine orally disintegrating tablets

The approved product is a generic version of the reference listed drug (RLD) Lamictal ODT by GlaxoSmithKline and is indicated for the treatment of epilepsy and bipolar disorder

Angelini Pharma and Quiver Bioscience team up to tackle genetic epilepsies

Under the deal, Quiver will receive an undisclosed advance payment and research support

Nia Therapeutics unveils first implantable brain interface for memory disorders

The SNS records neural activity from 60 channels across four brain regions—far exceeding current commercial devices